CJC-1295 for Age-Related Decline
How It Works
GHRH analog that stimulates pituitary GH release with sustained elevation.
Research Evidence
Research is ongoing. Consult current literature for latest evidence.
Dosing Protocol
100mcg 2-3x daily combined with Ipamorelin, or 2mg weekly (DAC version).
Important Considerations
- !Not FDA approved
- !Requires injection
- !Quality varies
- !Consult healthcare provider before use
- !Quality sourcing is critical
Frequently Asked Questions
Does CJC-1295 work for age-related decline?
Research is ongoing. Consult current literature for latest evidence. Research level: Phase 2 clinical trials.
How does CJC-1295 help with age-related decline?
GHRH analog that stimulates pituitary GH release with sustained elevation.
What is the CJC-1295 dosage for age-related decline?
100mcg 2-3x daily combined with Ipamorelin, or 2mg weekly (DAC version).
Is CJC-1295 safe for age-related decline?
Key considerations: Not FDA approved. Requires injection. Quality varies. Consult healthcare provider before use. Quality sourcing is critical. Always consult a healthcare provider.
How long until CJC-1295 works for age-related decline?
Results vary by individual and condition severity. Most users report initial effects within 2-4 weeks, with full benefits developing over 8-12 weeks of consistent use.